Raising Awareness about Adult Autism Spectrum Disorder

Sensibilizando para a Perturbação do Espetro do Autismo no Adulto

**KEYWORDS:** Attention Deficit Hyperactivity Disorder; Autistic Disorder; Neurodevelopmental Disorders; Transition to Adult Care

**PALAVRAS-CHAVE:** Perturbação do Deficit de Atenção com Hiperatividade; Perturbação Autística; Perturbação do Neurodesenvolvimento; Transição para Assistência do Adulto

Dear Editor,

Martins Halpern et al. presented the experience of their specialized center while highlighting the challenges of diagnosing and treating autism spectrum disorders in early infancy. However, problems in the approach of these and other neurodevelopmental disorders are not limited to the early stages of life. Their work prompted us to briefly highlight challenges arising in other phases of the life cycle and raise awareness of this condition.

Patients with neurodevelopmental disorders, including autism spectrum disorder (ASD) and attention deficit and hyperactivity disorder, are often lost in the transition from children and young people’s healthcare services to adult services.1,2 Patients who are not lost in this transition may prove even more challenging, since most have no previously known psychiatric history or a previously established diagnosis.3 Some individuals who suffer from these disorders present milder symptoms and often remain undiagnosed until adulthood. When eventually presenting to adult psychiatry services, these diagnoses are often also overlooked, with patients frequently diagnosed with different personality disorders (including schizoid and borderline personality disorder) or with other psychiatric comorbidities (depression, stress-related and anxiety disorders), and therefore deprived of specific psychosocial interventions or evidence-based treatments directed at the particular needs of patients with autism related disorders.2,4 Interestingly, individuals with high functioning ASD present more often to psychiatric services and yet they remain without a proper diagnosis until later stages in life.3

Overall, available national clinical recommendations provide general advice suggesting the assessment of adults presenting with inadequate social interaction, cognitive and behavioural rigidity, restricted interests and previous medical history of neurodevelopmental disorders.1,5 Although it is useful, the translation of these general principles in everyday clinical practice is not as straightforward as it may seem. Challenges include the clinical heterogeneity of ASD, ranging from complex genetic conditions with learning disability to high functioning individuals who adapted and developed strategies to overcome autistic deficits.3,4 Conceptualization of neurodevelopmental disorders, their neurobiology and different ways in which they affect functioning, quality of life and overall medical care, need to be considered and properly studied in order to ensure that minimal standards in the provision of care to individuals are met, including a smoother and well planned transition from child to adult healthcare services. Specific issues to be considered include the diagnostic challenges, psychiatric comorbidities, and lack of social support (reduced number of institutions, aging family caregivers, etc.).

The authors work in an institution with services providing care to adolescents and young adults in transition to adult psychiatric care (both in inpatient units and outpatient clinics), as well as a specialized outpatient clinic for patients with adult attention deficit disorder and neurodevelopmental disorders. This experience highlights the shortcomings felt in the care previously provided to these patients. The important message is that, although much has advanced since the initial descriptions of these disorders, there is still much to be done. It is essential to raise awareness and advocate for the specific medical and societal needs of adult individuals who suffer from the effect of these symptoms in their daily life, with profound impact in their general health and overall well-being.

**AUTHORS CONTRIBUTION**

TT: Design, draft of the paper, critical review.
JS: Critical review.

**COMPETING INTERESTS**

The authors have declared that no competing interests exist.

**FUNDING SOURCES**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**REFERENCES**

The EU Digital COVID Certificate: Should We Differentiate Between Previously Infected and Fully Vaccinated People?

The EU Digital COVID Certificate will be a proof that a person has been vaccinated against COVID-19, received a negative test result, or recovered from COVID-19. The EU has set the maximum validity period of the certificate of recovery at 180 days. There is no maximum validity foreseen for vaccination certificates.¹

What is the evidence behind this decision?

This decision has been taken based on the protection conferred regardless of the clinical severity of the primary infection.²⁻⁵ In fact, the immunological priming is the same. Both symptomatic and asymptomatic previously infected people showed a similar immediate and robust antibody production after a subsequent administration of one vaccine dose.⁶

We already have good immunologic and clinical evidence of long-lasting protection against reinfection in patients who recovered from infection.

What do we know about vaccinated people?

The best results published regarding vaccine effectiveness were those of Israel, with a follow-up period of seven days to three months after the second dose of the mRNA BNT162b2 vaccine. The protection was 92% against infection and 94% against symptomatic infection.⁷

Regarding efficacy against variants of concern (VOCs), no better protection is expected to be achieved by people who had been immunized through vaccination than by those who recovered from infection, since the immunological response is directed towards multiple viral antigens and not just the spike protein.⁸⁻¹⁰ In fact, a recent retrospective cohort study from Israel showed that the immunity acquired through infection conferred a better and longer lasting protection against infection, symptomatic disease and hospitalization caused by the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.¹⁰

The answer to the question whether the EU Digital COVID Certificate should differentiate between previously infected and fully vaccinated people should rely on the fact that, until now, previous infection has proved to be better and longer lasting than the vaccines.

So why decide in the opposite way?

PROTECTION OF HUMANS AND ANIMALS

The author declare that the procedures were followed according to the regulations established by the Clinical Research and Ethics Committee and to the Helsinki Declaration of the World Medical Association updated in 2013.

DATA CONFIDENTIALITY

The author declares that he followed the protocols in use at their working center regarding patients’ data publication.